GlassScriptPhysician profile
Yunna Jiang
NPI 1831415058
$12,240.18
in general payments reported to CMS, 2019-2025
49 companies · $2,952 in 2025
The $2,952 reported for 2025 was more than what 83% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $166 · 2021: $1,729 · 2022: $1,995 · 2023: $2,588 · 2024: $2,672 · 2025: $2,952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,412 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,411.82 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,461.39 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,400.44 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Senseonics, Incorporated | $800.00 | 2025 | Eversense |
| Sanofi-Aventis U.S. LLC | $765.98 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $762.96 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Amgen INC. | $705.59 | 2020-2025 | Evenity, Prolia, Tepezza |
| Dexcom, INC. | $622.83 | 2020-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $583.87 | 2019-2023 | Farxiga |
| Cequr Corporation | $484.82 | 2023-2025 | Cequr Simplicity |
| Abbott Laboratories | $406.14 | 2019-2025 | Freestyle Libre 3 |
| Insulet Corporation | $307.66 | 2021-2025 | Omnipod |
| Abbvie INC. | $306.81 | 2021-2025 | |
| Beta Bionics, INC. | $283.28 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Bayer Healthcare Pharmaceuticals INC. | $282.22 | 2021-2024 | |
| Corcept Therapeutics | $262.66 | 2022-2025 | Korlym |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yunna Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.